Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECESSITY Trial in Primary Sjögren's Syndrome
NCT05113004Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of leflunomide, mycophenolate mofetil and hydroxychloroquine in primary Sjögren's syndrome (6 cohorts), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Sjögren's Tool for Assessing Response to treatment at 24 weeks. Started Jan 2022; status: recruiting.
02
Drugs
leflunomidemycophenolate mofetilhydroxychloroquine
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT05113004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113004.